Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models

Simple item page
dc.citation.articleNumber449en_US
dc.citation.issueNumber3en_US
dc.citation.journalTitleVirusesen_US
dc.citation.volumeNumber14en_US
dc.contributor.authorYang, Haiqiangen_US
dc.contributor.authorCao, Jessicaen_US
dc.contributor.authorLin, Xiaoyangen_US
dc.contributor.authorYue, Jingwenen_US
dc.contributor.authorZieneldien, Tareken_US
dc.contributor.authorKim, Janiceen_US
dc.contributor.authorWang, Lianchunen_US
dc.contributor.authorFang, Jianminen_US
dc.contributor.authorHuang, Ruo-Panen_US
dc.contributor.authorBai, Yunen_US
dc.contributor.authorSneed, Kevinen_US
dc.contributor.authorCao, Chuanhaien_US
dc.date.accessioned2022-03-17T15:47:55Zen_US
dc.date.available2022-03-17T15:47:55Zen_US
dc.date.issued2022en_US
dc.description.abstractCoronavirus disease 2019 (COVID-19) has caused massive health and economic disasters worldwide. Although several vaccines have effectively slowed the spread of the virus, their long-term protection and effectiveness against viral variants are still uncertain. To address these potential shortcomings, this study proposes a peptide-based vaccine to prevent COVID-19. A total of 15 B cell epitopes of the wild-type severe acute respiratory coronavirus 2 (SARS-CoV-2) spike (S) protein were selected, and their HLA affinities predicted in silico. Peptides were divided into two groups and tested in C57BL/6 mice with either QS21 or Al(OH)3 as the adjuvant. Our results demonstrated that the peptide-based vaccine stimulated high and durable antibody responses in mice, with the T and B cell responses differing based on the type of adjuvant employed. Using epitope mapping, we showed that our peptide-based vaccine produced antibody patterns similar to those in COVID-19 convalescent individuals. Moreover, plasma from vaccinated mice and recovered COVID-19 humans had the same neutralizing activity when tested with a pseudo particle assay. Our data indicate that this adjuvant peptide-based vaccine can generate sustainable and effective B and T cell responses. Thus, we believe that our peptide-based vaccine can be a safe and effective vaccine against COVID-19, particularly because of the flexibility of including new peptides to prevent emerging SARS-CoV-2 variants and avoiding unwanted autoimmune responses.en_US
dc.identifier.citationYang, Haiqiang, Cao, Jessica, Lin, Xiaoyang, et al.. "Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models." <i>Viruses,</i> 14, no. 3 (2022) MDPI: https://doi.org/10.3390/v14030449.en_US
dc.identifier.doihttps://doi.org/10.3390/v14030449en_US
dc.identifier.urihttps://hdl.handle.net/1911/112023en_US
dc.publisherMDPIen_US
dc.rightsThis is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly citeden_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.titleDeveloping an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Modelsen_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpublisher versionen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
viruses-14-00449-v2.pdf
Size:
2.42 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Rice Coronavirus Research